Triumvira Immunologics (Triumvira), A Clinical-Stage Company Developing Novel, Targeted Autologous And Allogeneic T Cell Therapeutics That Co-Opt The Natural Biology Of T Cells To Treat Patients With Cancer, Announced Updated Positive Clinical Data From Its Ongoing Tactic-2 Phase 1/2 Trial Of Tac01-Her2 In Patients With Human Epidermal Growth Factor Receptor 2 (Her2) Positive Solid Tumours Will Be Shared In A Poster At The Society For Immunotherapy Of Cancer
